Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company generates news across medical device innovation, regulatory approvals, manufacturing expansions, and healthcare industry developments. As one of the world's largest medical technology manufacturers producing tens of billions of devices annually, BD's announcements often impact healthcare supply chains, public health initiatives, and clinical practice standards.
News coverage for BD typically encompasses product launches of safety-engineered medical devices, FDA clearances for new diagnostic instruments and drug delivery systems, and manufacturing capacity announcements that affect global medical supply availability. The company's role as a major supplier of syringes, needles, IV catheters, and diagnostic equipment means its production decisions can influence healthcare delivery capabilities, particularly during public health emergencies and vaccination campaigns.
Earnings reports reveal performance across BD's three business segments: Medical, Life Sciences, and Interventional. These disclosures provide insight into healthcare spending trends, adoption rates for new medical technologies, and geographic market dynamics across developed and emerging healthcare markets. Regulatory developments, including FDA warning letters, device recalls, or quality system issues, also generate significant news given the company's broad product portfolio and global manufacturing footprint.
Corporate developments such as acquisitions of medical device companies, divestitures of business units, strategic partnerships with pharmaceutical manufacturers, and manufacturing investments shape BD's competitive position. The company's interactions with group purchasing organizations, healthcare systems, and regulatory agencies produce news relevant to understanding healthcare economics and medical device industry dynamics.
Track BD news to monitor developments in medical device innovation, healthcare supply chain updates, regulatory compliance matters, and business performance across the company's medical technology portfolio. Understanding BD's announcements provides context on trends in hospital supply management, clinical diagnostics, and medication delivery technologies.
BD (NYSE: BDX) announced that the CE-marked BD Onclarity HPV Assay for the BD COR and BD Viper LT systems received WHO prequalification on November 17, 2025, enabling wider use in low- and middle-income countries.
The assay detects 14 high-risk HPV types with extended genotyping (six individual types plus three genotype groups), supports self-collection including at-home where CE is recognized, and targets improved risk stratification and follow-up. The BD COR offers ~1,650-test capacity and up to 1,000 results in 24 hours; BD Viper LT provides compact, decentralized molecular testing.
BD (NYSE: BDX) announced on November 13, 2025 that Duncan Regional Hospital is the first U.S. hospital to go live with BD Alaris™ EMR Infusion Interoperability integrated with MEDITECH. The integration enables bi-directional communication between MEDITECH and Alaris infusion pumps, allowing clinicians to scan to verify patients, medications and pumps; send infusion orders from MEDITECH to pumps; and receive infusion status back into the EHR.
The rollout expands BD's market-leading interoperability—now live at more than 960 U.S. sites—to all three leading U.S. EHRs, and BD reports a pace of about 12 new site activations per month.
BD (NYSE: BDX) on Nov 12, 2025 introduced the PureWick™ Portable Collection System, a battery-powered, non-invasive urine management device designed for wheelchair users and mobile use.
Key facts: the device offers up to 8 hours battery life, is mountable or carriable, compatible with PureWick™ male and female external catheters, and is sold via PureWickAtHome.com and phone ordering. The PureWick portfolio has sold > 55 million external catheters and is used in > 4,500 hospitals and rehab facilities in the U.S.; a survey of 150 users/caregivers found > 90% would recommend the PureWick urine collection system. BD positions the portable unit to improve mobility, discretion, and skin protection for people managing urinary incontinence.
BD (NYSE: BDX) reported fiscal 2025 Q4 revenue of $5.9B (+8.3% reported, +7.0% FXN, +3.9% organic) and fiscal 2025 revenue of $21.8B (+8.2% reported, +7.7% FXN, +2.9% organic).
Q4 GAAP diluted EPS was $1.72 and adjusted diluted EPS was $3.96. Full-year GAAP EPS was $5.82 (down 0.7%) and adjusted diluted EPS was $14.40 (+9.6%). Adjusted operating margin improved to 25.0%; GAAP operating margin was 11.8%.
BD returned $2.2B to shareholders in FY25 and provided FY26 guidance of low single-digit revenue growth and adjusted diluted EPS of $14.75–$15.05. Management reiterated the planned combination of Biosciences and Diagnostic Solutions with Waters around end of Q1 CY2026.
BD (NYSE: BDX) declared a quarterly dividend of $1.05 per share, a 1.0% increase from the prior quarter. The dividend is payable on December 31, 2025 to holders of record on December 8, 2025.
The company set an indicated annual dividend rate for fiscal year 2026 of $4.20 per share. This marks the 54th consecutive fiscal year BD has raised its dividend, maintaining its membership in the S&P 500 Dividend Aristocrats Index. Management linked the increase to confidence in BD's long-term outlook during execution of the Waters RMT transaction.
BD (NYSE: BDX) announced on November 4, 2025 that the AGILITY IDE study has achieved full enrollment of the common and external iliac artery cohort (n=118) for the Revello™ Vascular Covered Stent in peripheral artery disease (PAD).
The multi-center, prospective AGILITY study (NCT06111469) is enrolling at up to 45 sites across the United States, Europe, Australia and New Zealand and includes a second cohort for superficial femoral and proximal popliteal arteries (n=223) with enrollment ongoing. The milestone was announced during a late-breaking presentation at VIVA 2025 by Dr. Sean Lyden.
BD (NYSE: BDX) received FDA 510(k) clearance and CE-IVDR/CE marking for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR™ System on Nov 3, 2025.
The molecular panels use PCR on the BD COR system to detect a broad range of GI bacterial pathogens from a single stool swab and run on a high-throughput automated system with capacity for nearly 1,650 tests and up to 1,000 sample results in 24 hours, plus up to 7 hours walk-away time and room-temperature reagents.
BD (NYSE: BDX) announced an IVDR-certified, dry self-collection swab and fully automated lab workflow for HPV testing outside the United States on Oct 22, 2025. The solution enables safe at-home sample collection without liquids, supports mailing to labs, and requires no manual sample preparation for clinical laboratory technologists when used with the BD COR™ System.
Key technical points:
- 30-day dry sample stability, including up to 5 days at 45°C and 4 freeze/thaw cycles
- Onboard Rehydration Technology to eliminate manual prep
- Barcode-driven unified workflow and internal cellular control for specimen integrity
The product is expected to be commercially available across IVDR-recognized markets in the coming months.
BD (NYSE: BDX) on Oct 20, 2025 launched the BD Incada™ Connected Care Platform, an AI-enabled, AWS-based cloud platform that unifies BD device data into a single ecosystem and supports analytics for nearly 3 million smart connected BD devices.
At the same time BD introduced the next-generation BD Pyxis™ Pro Dispensing Solution, a stackable automated medication dispenser that adds capacity (up to 538 multi-access or 98 secure pockets) in a similar footprint, and adds security, RFID badge scanning, wireless barcode scanning and illuminated bins.
The combined offering emphasizes enterprise-wide medication visibility, natural-language analytics, customizable dashboards, and secure cloud storage aimed at reducing medication waste, improving labor efficiency, and speeding point-of-care access. BD notes the Pyxis system processes about 9.8 million transactions per day.
BD (NYSE: BDX) celebrated 65 years of manufacturing at its Broken Bow, Nebraska facility on Oct. 16, 2025. The site opened Oct. 18, 1960 and has grown from a 13,753-square-foot plant with 20 associates to a 310,000-square-foot facility employing nearly 600 associates.
Broken Bow is described as the world's largest manufacturer of BD Vacutainer® tubes, producing billions of tubes and other collection products annually. BD reports more than $50 million invested in Nebraska since 2020 and announced a separate >$35 million investment and 50 jobs at its Columbus facility. BD operates 30+ U.S. sites with ~10,000 employees.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
